The designer cytokine IC7: a novel therapy for the treatment of type 2 Diabetes

设计师细胞因子 IC7：治疗 2 型糖尿病的新疗法

• 批准号: nhmrc : GNT1156511
• 金额: $ 108.16万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/designer-cytokine-ic7-2-diabetes/1378936
• 关键词: designer; cytokine; IC7; novel; therapy

Obesity is a world pandemic in the new millennium. It leads to many diseases including type 2 diabetes (T2D). T2D is degenerative, leading to profound health effects. Current therapies are inadequate and approximately half of those diagnosed and being treated are unable to control their disease. Ongoing work in our laboratories has led to the development of a novel protein IC7 which we will test as novel therapeutic strategy for the treatment of T2D.

肥胖症是新千年的世界性流行病。它会导致许多疾病，包括2型糖尿病(T2D)。T2D是退行性的，会对健康产生深远的影响。目前的治疗方法是不够的，大约一半的确诊和正在接受治疗的人无法控制他们的疾病。我们实验室正在进行的工作导致了一种新的蛋白IC7的开发，我们将测试该蛋白作为治疗T2D的新治疗策略。